Bora Biologics, a major contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics’ position as a premier biologics CDMO.
The expanded facility will feature two 2000L Cytiva XDR bioreactors and seed train, providing Bora Biologics’ clients with robust and scalable biologics manufacturing solutions.
Bora Biologics’ San Diego facility currently offers a comprehensive range of GMP manufacturing suites, including 50L, 250L and 1000L single-use bioreactors dedicated to mammalian cell culture, and a dedicated microbial GMP suite equipped with a 150L stainless steel fermenter and a 300L single-use fermenter expansion capability.
This expansion underscores Bora Biologics’ dedication to providing its clients with cutting-edge manufacturing capabilities and its commitment to supporting the development and commercialization of life-saving therapies.